228 patients enrolled

Part A – 68 patients

Not treated (n = 4)

Placebo (n = 16)

1 discontinued
(1) Admin. decision

15 completed study

AMG 108 100 mg IV (n = 12)

0 discontinued

12 completed study

AMG 108 300 mg IV (n = 12)

1 discontinued
(1) Death

11 completed study

AMG 108 300 mg SC (n = 12)

0 discontinued

12 completed study

AMG 108 75 mg SC (n = 12)

0 discontinued

12 completed study

Part B – 160 patients

Not treated (n = 1)

Placebo (n = 79)

7 discontinued
(1) Admin. decision
(3) Withdrew consent
(4) Withdrew consent
(2) Lost to follow-up
(1) Protocol deviation

72 completed study

AMG 108 300 mg SC (n = 80)

9 discontinued
(2) Admin. decision
(1) AE

71 completed study

0 discontinued

0 discontinued

0 discontinued

1 discontinued
(1) Death

12 completed study

1 discontinued
(1) AE

11 completed study

(3) Withdrew consent

12 completed study

(2) Lost to follow-up

12 completed study

(1) Protocol deviation